CART-T/CRS/ICANS

Author: Dr. Danyal Ladha, University of Ottawa
Reviewer: Dr. Michael Kennah, Transplant and Cellular Therapy Program, University of Ottawa

Objectives

At the end of the self-assessment module, participants will be able to:

1. Describe the approved indications for CAR T-cell therapy in Canada.
2. Describe the adverse events associated with CAR T-cell therapy.
3. Develop an approach to the evaluation and management of common adverse events associated with CAR T-cell therapy.

CHS Scientific Planning Committee Members (2021-22)

Dr. Joanne Britto – Resident Physician, Hematology-Oncology
Dr. Yan Xu – Fellow Physician, Hematology
Dr. Siraj Mithoowani – Clinical Hematologist at St. Joseph’s Healthcare, Hamilton
Dr. Hassan Sibai – Assistant Professor of Medicine, Faculty of Medicine, University of Toronto and Staff Physician, Division of Medical Hematology & Oncology, Princess Margaret Cancer Centre

Conflicts of Interest: None